Supplementary Data from Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4⁺ Th1 Responses and Potential Use as a Cancer Vaccine

Abstract

Supplementary Data from Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4<sup>+</sup> Th1 Responses and Potential Use as a Cancer Vaccine